Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel

LMB‐100 is a novel immune‐conjugate (immunotoxin) that targets mesothelin. A phase 1/2 clinical trial was conducted (NCT02810418) with primary objectives assessing the safety and efficacy of LMB‐100 ± nab‐paclitaxel. Participant blood samples were analyzed for changes in serum cytokines and circulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pegna, Guillaume Joe, Lee, Min‐Jung, Peer, Cody J., Ahmad, Mehwish I., Venzon, David J., Yu, Yunkai, Yuno, Akira, Steinberg, Seth M., Cao, Liang, Figg, William D., Donahue, Renee N., Hassan, Raffit, Pastan, Ira, Trepel, Jane B., Alewine, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972172/
https://www.ncbi.nlm.nih.gov/pubmed/36208017
http://dx.doi.org/10.1002/cam4.5290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972172/
https://www.ncbi.nlm.nih.gov/pubmed/36208017
http://dx.doi.org/10.1002/cam4.5290

Ejemplares similares